| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
MRC Toxicology Unit, Hodgkin Building, University of Leicester, P.O. Box 138, Lancaster Road, Leicester LE1 9HN, United Kingdom
Tamoxifen administered in the diet (420 ppm) to Wistar rats (TOX:P) for only 3 months caused cumulative hepatic DNA damage as assessed by 32P-postlabeling, consistent with the proposal that tamoxifen is a genotoxic carcinogen in this species. Promotion of tumor development with phenobarbital after discontinuation of dietary tamoxifen resulted in the formation of liver carcinomas after 9 months. At 12 and 20 months in this study, the majority of these rats had liver carcinomas. Rats treated with tamoxifen for 3 months but not promoted with phenobarbital also developed liver tumors over a longer period of time. These tumors were predominantly adenomas, with one carcinoma, and occurred at a lower incidence than the tumors produced by promotion with phenobarbital. Rats treated with phenobarbital alone did not develop tumors after 20 months. Tamoxifen-induced DNA adducts were relatively persistent, with only a 38% decrease 3 months after tamoxifen treatment had been discontinued. This demonstrates that, in a susceptible species (the rat), tamoxifen can cause initiation of liver cancer after only 3 months exposure. It is proposed that the persistence of such DNA adducts may account for the ability of phenobarbital to promote a high incidence of liver carcinoma, even after discontinuation of tamoxifen treatment. These data are relevant to the concern for women given prophylactic tamoxifen for long periods in that even if there is a relatively small amount of cumulative tamoxifen-induced liver DNA damage, liver tumors could be promoted by other agents, even after the cessation of tamoxifen treatment.
1 To whom requests for reprints should be addressed.
Received 9/20/94. Accepted 12/ 1/94.
This article has been cited by other articles:
|
|
 |
|
  K. Brown Is tamoxifen a genotoxic carcinogen in women? Mutagenesis, September 1, 2009; 24(5): 391 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Schild, R. L. Divi, F. A. Beland, M. I. Churchwell, D. R. Doerge, G. Gamboa da Costa, M. M. Marques, and M. C. Poirier Formation of Tamoxifen-DNA Adducts in Multiple Organs of Adult Female Cynomolgus Monkeys Dosed with Tamoxifen for 30 Days Cancer Res., September 15, 2003; 63(18): 5999 - 6003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Maiti and G. Chen Tamoxifen Induction of Aryl Sulfotransferase and Hydroxysteroid Sulfotransferase in Male and Female Rat Liver and Intestine Drug Metab. Dispos., May 1, 2003; 31(5): 637 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. N.H. White, P. Carthew, R. Davies, J. Styles, K. Brown, J. E. Brown, L. L. Smith, and E. A. Martin Short-term dosing of {{alpha}}-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats Carcinogenesis, April 1, 2001; 22(4): 553 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Boocock, J. L. Maggs, K. Brown, I. N.H. White, and B.K. Park Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of {alpha}-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts Carcinogenesis, October 1, 2000; 21(10): 1851 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Carthew, R. E. Edwards, B. M. Nolan, E. A. Martin, R. T. Heydon, I. N.H. White, and M. J. Tucker Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia Carcinogenesis, April 1, 2000; 21(4): 793 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Divi, M. R. Osborne, A. Hewer, D. H. Phillips, and M. C. Poirier Tamoxifen-DNA Adduct Formation in Rat Liver Determined by Immunoassay and 32P-Postlabeling Cancer Res., October 1, 1999; 59(19): 4829 - 4833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Brown, R. T. Heydon, R. Jukes, I. N.H. White, and E. A. Martin Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen Carcinogenesis, October 1, 1999; 20(10): 2011 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. N.H. White The tamoxifen dilemma Carcinogenesis, July 1, 1999; 20(7): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Davies, T. W. Gant, L. L. Smith, and J. A. Styles Tamoxifen induces G:C->T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5'-CpG-3' dinucleotide sequences as found in the lacI transgene Carcinogenesis, July 1, 1999; 20(7): 1351 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Tombolan, D. Renault, D. Brault, M. Guffroy, O. Perin-Roussel, F. Perin, and V. Thybaud Kinetics of induction of DNA adducts, cell proliferation and gene mutations in the liver of Muta(TM)Mice treated with 5,9-dimethyldibenzo[c,g]carbazole Carcinogenesis, January 1, 1999; 20(1): 125 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Boocock, J. L. Maggs, I. N.H. White, and B. K. Park {alpha}-Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro Carcinogenesis, January 1, 1999; 20(1): 153 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Williams Safety Assessment of Pharmaceuticals: Examples of Inadequate Assessments and a Mechanistic Approach to Assuring Adequate Assessment Toxicol Pathol, January 1, 1997; 25(1): 32 - 38. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
